

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

July 2017

Vol. 45, No. 7

CONTENTS

ARTICLES

- In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s. *Zhican Wang, Ying Fang, Juli Teague, Hansen Wong, Christophe Morisseau, Bruce D. Hammock, Dan A. Rock, and Zhengping Wang* **712**
- Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. *Rhishikesh Thakare, Hongying Gao, Rachel E. Kosa, Yi-An Bi, Manthena V. S. Varma, Matthew A. Cerny, Raman Sharma, Max Kuhn, Bingshou Huang, Yiping Liu, Aijia Yu, Gregory S. Walker, Mark Niosi, Larry Tremaine, Yazen Alhouti, and A. David Rodrigues* **721**
- Transporter-Mediated Disposition, Clinical Pharmacokinetics and Cholestatic Potential of Glyburide and Its Primary Active Metabolites. *Rui Li, Yi-an Bi, Anna Vildhede, Renato J. Scialis, Sumathy Mathialagan, Xin Yang, Lisa D. Marroquin, Jian Lin, and Manthena V.S. Varma* **737**
- Crypt Organoid Culture as an in Vitro Model in Drug Metabolism and Cytotoxicity Studies. *Wenqi Lu, Eva Rettenmeier, Miles Paszek, Mei-Fei Yueh, Robert H. Tukey, Jocelyn Trottier, Olivier Barbier, and Shujuan Chen* **748**
- Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir. *Mohamad Shebley, Jinrong Liu, Olga Kavetskaia, Jens Sydor, Sonia M. de Morais, Volker Fischer, Marjoleen J.M.A. Nijssen, and Daniel A.J. Bow* **755**
- Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters. *David J. Wagner, Jennifer E. Sager, Haichuan Duan, Nina Isoherranen, and Joanne Wang* . . . **770**
- Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins. *Takashi Yoshikado, Kota Toshimoto, Tomohisa Nakada, Kazuaki Ikejiri, Hiroyuki Kusuhara, Kazuya Maeda, and Yuichi Sugiyama* **779**
- Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor- α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models. *Xi Chen, Debra C. DuBois, Richard R. Almon, and William J. Jusko* **790**
- Characterization and Interspecies Scaling of rhTNF- α Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models. *Xi Chen, Debra C. DuBois, Richard R. Almon, and William J. Jusko* . . **798**
- Characterization of the Tissue Distribution of the Mouse *Cyp2c* Subfamily by Quantitative PCR Analysis. *Joan P. Graves, Artiom Gruzdev, J. Alyce Bradbury, Laura M. DeGraff, Matthew L. Edin, and Darryl C. Zeldin* **807**
- Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro. *David Pearson, H. Markus Weiss, Yi Jin, Jan Jaap van Lier, Veit J. Erpenbeck, Ulrike Glaenzel, Peter End, Ralph Woessner, Fabian Eggimann, and Gian Camenisch* **817**
- Penetration Route of the Selective Glucocorticoid Receptor Agonist SA22465 and Betamethasone into Rabbit Meibomian Gland Based on Pharmacokinetics and Autoradiography. *Nagayoshi Asano, Kenji Ueda, and Kouichi Kawazu* **826**
- Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen. *Xiaonan Li, Debra C. DuBois, Dawei Song, Richard R. Almon, William J. Jusko, and Xijing Chen* **834**

Downloaded from dmd.aspetjournals.org at ASPET Journals on May 29, 2024

Continued on next page

Inhibition of the *all-trans* Retinoic Acid (*atRA*) Hydroxylases CYP26A1 and CYP26B1 Results in Dynamic, Tissue-Specific Changes in Endogenous *atRA* Signaling. *Faith Stevison, Cathryn Hogarth, Sasmita Tripathy, Travis Kent, and Nina Isoherranen* **846**

▣ Integrated Assessment of Diclofenac Biotransformation, Pharmacokinetics, and Omics-Based Toxicity in a Three-Dimensional Human Liver-Immunocompetent Coculture System. *Ujjal Sarkar, Kodihalli C. Ravindra, Emma Large, Carissa L. Young, Dinelia Rivera-Burgos, Jiajie Yu, Murat Cirit, David J. Hughes, John S. Wishnok, Douglas A. Lauffenburger, Linda G. Griffith, and Steven R. Tannenbaum* **855**

▣ RNA Sequencing Reveals Age and Species Differences of Constitutive Androstane Receptor-Targeted Drug-Processing Genes in the Liver. *Sunny Lihua Cheng, Theo K. Bammler, and Julia Yue Cui* **867**

SHORT COMMUNICATIONS

▣ High-Fat Diet Feeding Alters Expression of Hepatic Drug-Metabolizing Enzymes in Mice. *Miaoran Ning and Hyunyoung Jeong* **707**

Long-Term Stability of Cryopreserved Human Hepatocytes: Evaluation of Phase I and II Drug-Metabolizing Enzyme Activities and CYP3A4/5 Induction for More than a Decade. *Miyako Sudo, Mitsuhiro Nishihara, Junzo Takahashi, and Satoru Asahi* . . . **734**

▣ LKY-047: First Selective Inhibitor of Cytochrome P450 2J2. *Nguyen Minh Phuc, Zhexue Wu, Yuseok O, Jee-Hyun Lee, Sangtaek Oh, Gyu-Yong Song, and Kwang-Hyeon Liu* **765**

ERRATUM

Correction to “Tramadol Metabolism to O-Desmethyl Tramadol (M1) and N-Desmethyl Tramadol (M2) by Dog Liver Microsomes: Species Comparison and Identification of Responsible Canine Cytochrome P450s”. **706**

▣ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Time-course autoradiograms of eye and eyelid sections indicating the distribution of 14C-SA22465 following a single ocular administration (1.5 mg/50 μ L/eye) by Asano et al. ([dx.doi.org/10.1124/dmd.117.075473](https://doi.org/10.1124/dmd.117.075473)).